Monthly Dispensed Prescriptions for Extendryl(R) Product Line Increases 146%

NORCROSS, Ga -- Auriga Laboratories, Inc. (OTCBB:ARGA), a specialty pharmaceutical company with products for the treatment of acute respiratory diseases, dermatological conditions, and Xerostomia, reported today its sales force has exceeded 100 associates nationwide. This number comprises the company's sales associates currently detailing products, those in training, and those who will receive training over the next five weeks.

"This major milestone reflects Auriga's ability to execute its strategy to drive strong sales growth using commission-based associates," said Philip S. Pesin, Auriga's CEO. "This is especially important because I believe we are the most sales-driven company in our industry, with the most innovative and rewarding program for our associates. We have built a strong portfolio of products and established important distribution relationships which have provided them confidence and great incentives."

For Auriga, the success of this strategy is also appearing in real market numbers. Independent monthly IMS data shows Auriga's total dispensed prescriptions for its Extendryl family of products increased 146% in December 2006, as compared to December 2005.

Added Pesin, "We see this is as only the beginning, as we anticipate our fast-growing sales force, led by our new national sales director, Richard Sampson, will continue to take Auriga to new levels."

The company reported on December 14, 2006 that its sales force had expanded to 56 sales associates from nine in less than six months. It is now targeting 150 associates by the end of the first quarter 2007.

"Auriga presents a tremendous and rare sales opportunity for our associates," said Sampson. "Supported by a brilliant and unique business model, it is attracting some very strong players. This dedicated and motivated sales team will support the nationwide roll out of several new products over the coming months."

During this quarter, Auriga plans to launch Aquoral(TM), a prescription-only product designed to treat the widespread condition of Xerostomia (or dry mouth) and its Zinx(TM) family of respiratory prescription and over-the-counter products.

About Auriga Laboratories(TM)

Auriga Laboratories is a specialty pharmaceutical company capitalizing on high-revenue markets and opportunities in the pharmaceutical industry through proactive sales, integrated marketing, and advanced in-house drug development capabilities. The company's high-growth business model combines acquisition of proven brand names, powerful product development strategies and rapidly-growing national sales teams and marketing operations. Auriga acquires valuable brand portfolios that are no longer a strategic focus for large pharmaceutical companies, then capitalizes on untapped marketplace opportunities through brand extension and directed sales/marketing programs. The company's drug-development pipeline leverages novel material science and advanced drug delivery technologies to produce improved formulations of successful brands to further expand markets, sales and clinical indications for proven, successful products. Auriga's exclusive prescription product portfolio currently includes Aquoral(TM) for the treatment of Xerostomia, Akurza(TM) and Xyralid(TM) dermatology products, and the Zinx(TM), Extendryl®, and Levall® families of products for relief of symptoms associated with a range of acute respiratory diseases. For more information, visit: www.aurigalabs.com.

Forward-Looking Statements

The information contained herein includes forward-looking statements. These statements relate to future events or to the company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause its actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to its operations, results of operations, growth strategy and liquidity. The company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Statements regarding the company's ability to increase its sales force and the success of such sales force in selling its products in light of competitive and other factors, the regulatory status and/or regulatory compliance of its products, the company's ability to secure additional financing, its ability to sustain market acceptance for its products, its dependence on collaborators, the company's ability to find and execute strategic transactions, its potential exposure to litigation, the company's exposure to product liability claims, and the company's prices, future revenues and income and cash flows and other statements that are not historical facts contain predictions, estimates and other forward-looking statements. Although the company believes that its expectations are based on reasonable assumptions, it can give no assurance that its goals will be achieved and these statements will prove to be accurate. Important factors could cause actual results to differ materially from those included in the forward-looking statements.

Contact:

Auriga Laboratories, Inc.
Philip Pesin, 877-287-4428
investors@aurigalabs.com
or
Investor Relations
Liolios Group, Inc.
Scott Liolios or Ron Both, 949-574-3860